Valley National Advisers Inc. raised its stake in Sanofi (NYSE:SNY) by 4.3% during the third quarter, Holdings Channel reports. The firm owned 15,838 shares of the company’s stock after buying an additional 653 shares during the period. Valley National Advisers Inc.’s holdings in Sanofi were worth $605,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in SNY. Bessemer Group Inc. boosted its stake in Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock valued at $144,000 after buying an additional 1,500 shares during the period. Signaturefd LLC boosted its stake in Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock valued at $146,000 after buying an additional 490 shares during the period. JFS Wealth Advisors LLC boosted its stake in Sanofi by 1.9% in the third quarter. JFS Wealth Advisors LLC now owns 4,035 shares of the company’s stock valued at $154,000 after buying an additional 74 shares during the period. Weik Investment Services Inc. acquired a new stake in Sanofi during the second quarter valued at $222,000. Finally, Rehmann Capital Advisory Group boosted its stake in Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock valued at $233,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 9.75% of the company’s stock.
Sanofi (NYSE:SNY) traded down 1.45% during mid-day trading on Thursday, hitting $40.17. The company’s stock had a trading volume of 958,621 shares. The company has a market cap of $103.40 billion, a P/E ratio of 23.23 and a beta of 0.97. Sanofi has a 12-month low of $36.81 and a 12-month high of $44.50. The firm’s 50-day moving average is $40.20 and its 200-day moving average is $39.85.
Several research analysts have recently issued reports on the company. Leerink Swann reissued an “outperform” rating on shares of Sanofi in a research report on Tuesday, January 10th. Goldman Sachs Group Inc. reissued a “hold” rating on shares of Sanofi in a research report on Sunday, January 8th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, November 29th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research report on Tuesday, December 27th. Finally, Piper Jaffray Cos. assumed coverage on Sanofi in a research report on Friday, September 23rd. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $60.00.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).